Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Strategies; Reimbursement

Set Alert for Pricing Strategies and Reimbursement

Pricing Strategies

Concessions Hit And Miss As Some UK Prices Treble

Concession prices granted by the UK Department of Health and Social Care targeted some, but not all, of the fastest-rising generics prices in November. The average cost of some presentations more than trebled, according to the latest figures from WaveData.

Market Intelligence United Kingdom

UK Price Increases Add To Pharmacy Burden

A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.

Pricing Strategies Generic Drugs

Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation

Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
Generic Drugs Legal Issues

Consensus Is Essential To Find Best Value-Added Path

Finding a consensus across European stakeholders on how best to recognize and reward the benefits of value added medicines is key to the sector’s success, says Arun Narayan – chairman of the value added medicines sector group at Medicines for Europe and also head of global portfolio strategy and head of European business operations at Mylan – in an exclusive interview with Generics Bulletin.

Value-Added Medicines Regulation

Sandoz Is Satisfied With US Pegfilgrastim Start

Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.

Biosimilars Launches

UK Price Shifts Do Not Always Follow Reimbursement

Price movements seen among recently-launched generics in the UK do not always reflect changes in reimbursement prices, according to the latest figures from WaveData.

Market Intelligence United Kingdom
See All
UsernamePublicRestriction

Register